secwatch.observer — SEC 8-K summary
======================================

Issuer:     TG THERAPEUTICS, INC. (TGTX)
CIK:        0001001316
Form:       8-K
Filed at:   2026-08-03T11:05:58+00:00
Accession:  0001437749-26-025304
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TG Therapeutics Q2 2026 revenue $240M, raises FY2026 BRIUMVI guidance to ~$890-905M
--------------------------------------------------------------------------------

- Q2 2026 total global revenue ~$240M; BRIUMVI U.S. net product revenue $227.7M, up 64% YoY.
- Raises FY2026 BRIUMVI U.S. net product revenue target to ~$890-905M; total global revenue target ~$950M.
- Net income $7.8M in Q2 2026 vs $28.2M in Q2 2025; R&D expense increased to $95.3M due to subcutaneous manufacturing.
- Positive Phase 3 ENHANCE trial met primary endpoint; single 600mg infusion regimen eliminates Day 15 infusion.
- Cash position $612.3M as of June 30, 2026; operating expense target $350-400M (excl. non-cash comp) plus ~$100M for subcutaneous mfg.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/0001437749-26-025304-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1001316/000143774926025304/tgtx20260730_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-025304

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer